Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
VTYX 
Ventyx Biosciences Inc (VTYX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: VTYX (3-star) is a STRONG-BUY. BUY since 2 days. Simulated Profits (-0.22%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $13.38
1 Year Target Price $13.38
| 5 | Strong Buy |
| 1 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -14.02% | Avg. Invested days 21 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 993.02M USD | Price to earnings Ratio - | 1Y Target Price 13.38 |
Price to earnings Ratio - | 1Y Target Price 13.38 | ||
Volume (30-day avg) 9 | Beta 1.24 | 52 Weeks Range 0.78 - 15.34 | Updated Date 01/9/2026 |
52 Weeks Range 0.78 - 15.34 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.49 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -28.47% | Return on Equity (TTM) -45.35% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 810408048 | Price to Sales(TTM) - |
Enterprise Value 810408048 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -22.93 | Shares Outstanding 71750148 | Shares Floating 60016182 |
Shares Outstanding 71750148 | Shares Floating 60016182 | ||
Percent Insiders 4.22 | Percent Institutions 68.19 |
Upturn AI SWOT
Ventyx Biosciences Inc
Company Overview
History and Background
Ventyx Biosciences Inc. is a clinical-stage biopharmaceutical company founded in 2018. Its primary focus is on developing novel small molecule therapeutics for inflammatory diseases. A significant milestone was its initial public offering (IPO) in 2022, which provided capital for its clinical development programs. The company has evolved by strategically advancing its pipeline candidates through preclinical and early clinical stages.
Core Business Areas
- Inflammatory Diseases Therapeutics: Ventyx Biosciences is dedicated to discovering and developing orally administered small molecule inhibitors targeting key inflammatory pathways. Their approach aims to address significant unmet medical needs in various autoimmune and inflammatory conditions.
Leadership and Structure
Ventyx Biosciences is led by a management team with extensive experience in drug development and the biopharmaceutical industry. The organizational structure is typical for a clinical-stage biotech, with departments focused on research and development, clinical operations, regulatory affairs, and corporate functions.
Top Products and Market Share
Key Offerings
- VTX002: A selective TYK2 inhibitor intended for the treatment of inflammatory diseases. It has advanced into Phase 2 clinical trials. Competitors include companies developing other TYK2 inhibitors or biologics for similar indications.
- VTX003: A selective NLRP3 inhibitor. This candidate is in preclinical development, with potential applications in inflammatory conditions. Competitors include other companies exploring NLRP3 inhibition.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly in the inflammatory diseases space, is characterized by significant innovation, high R&D costs, and a competitive landscape. The market is driven by the need for more effective and convenient treatments for chronic inflammatory conditions.
Positioning
Ventyx Biosciences is positioned as a clinical-stage biotech with a focus on oral small molecule therapies for inflammatory diseases. Its competitive advantage lies in its targeted approach to specific inflammatory pathways and its pipeline of differentiated drug candidates.
Total Addressable Market (TAM)
The global market for inflammatory disease treatments is substantial and projected to grow significantly. Ventyx Biosciences, by targeting specific inflammatory conditions, aims to capture a share of this large and growing TAM with its novel therapeutics.
Upturn SWOT Analysis
Strengths
- Pipeline of differentiated small molecule inhibitors targeting key inflammatory pathways.
- Experienced management team with a track record in drug development.
- Focus on oral therapies, which can offer convenience over injectables.
- Recent IPO provides funding for clinical development.
Weaknesses
- Clinical-stage company with no approved products, leading to inherent development risks.
- Reliance on successful clinical trial outcomes.
- Limited brand recognition and market presence compared to larger pharmaceutical companies.
- Significant capital requirements for ongoing R&D.
Opportunities
- Significant unmet medical needs in various inflammatory and autoimmune diseases.
- Potential for strategic partnerships or acquisitions by larger pharmaceutical companies.
- Advancement of pipeline candidates through clinical trials and potential regulatory approval.
- Expansion into new indications for existing drug candidates.
Threats
- Clinical trial failures or delays.
- Intense competition from established pharmaceutical companies and other biotech firms.
- Regulatory hurdles and lengthy approval processes.
- Pricing pressures and market access challenges.
- Patent expirations and generic competition for related therapies.
Competitors and Market Share
Key Competitors
- AbbVie Inc. (ABBV)
- Eli Lilly and Company (LLY)
- Pfizer Inc. (PFE)
- Bristol Myers Squibb Company (BMY)
- Amgen Inc. (AMGN)
Competitive Landscape
Ventyx Biosciences faces intense competition from large pharmaceutical companies with established portfolios in inflammatory diseases and other biotechs with similar pipeline targets. Ventyx's advantage lies in its focus on specific mechanisms and oral delivery, but it lacks the scale and market presence of its larger rivals.
Growth Trajectory and Initiatives
Historical Growth: Ventyx Biosciences has experienced growth primarily in its operational scale and pipeline advancement since its inception. This growth is reflected in increased R&D investment and team expansion.
Future Projections: Future growth projections for Ventyx Biosciences are heavily dependent on the successful clinical development and regulatory approval of its lead drug candidates, particularly VTX002. Analyst estimates will focus on potential peak sales if approved.
Recent Initiatives: Recent initiatives likely include the progression of VTX002 into Phase 2 studies, advancement of VTX003 into preclinical development, and ongoing efforts to secure sufficient funding for clinical trials.
Summary
Ventyx Biosciences is a promising clinical-stage biopharmaceutical company focused on developing innovative oral therapies for inflammatory diseases. Its strength lies in its differentiated pipeline targeting key inflammatory pathways. However, it faces significant risks associated with clinical development, competition, and the need for substantial funding. Success hinges on successfully advancing its lead candidates through clinical trials and gaining regulatory approval.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Investor Relations Websites
- Financial News Outlets
- Industry Analyst Reports
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. The analysis is based on publicly available information and is subject to change. Investing in clinical-stage biotechnology companies involves significant risk, including the potential loss of principal. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ventyx Biosciences Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2021-10-21 | Founder, CEO, President & Director Dr. Raju S. Mohan Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 83 | Website https://ventyxbio.com |
Full time employees 83 | Website https://ventyxbio.com | ||
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in Phase 2a trial for patients with early Parkinson's disease and is in Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.